Skip to main content

Table 2 Distribution of first episode of leprosy reactions and main clinical manifestations developed by patients stratified by R&J groups

From: Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil

  I TT BT BB BL LL TOTAL (%)
Reactions 0 6 105 31 190 86 418 (55.5)
 RR 0 2 28 16 92 0 138 (18.3)
 ENL 0 0 0 0 13 28 41 (5.4)
 Necrotising ENL 0 0 0 0 0 1 1 (0.1)
 Lymphadenopathy 0 0 0 0 1 1 2 (0.2)
 Reaction hand and foot 0 0 4 1 8 6 19 (2.5)
 ENL + Polymorphic Erythema 0 0 0 0 1 0 1 (0.1)
 ENL + Orchitis 0 0 0 0 0 1 1 (0.1)
 ENL + Arthritis 0 0 0 0 0 1 1 (0.1)
 ENL + Lymphadenopathy 0 0 0 0 1 1 2 (0.3)
 ENL + reactional hand and foot 0 0 0 0 0 3 3 (0.4)
 Mixed reaction / Type 1 + Type 2 0 0 0 1 6 1 8 (1.1)
 Neuritis 0 3 59 8 43 36 149 (19.8)
 Neuritis + RR 0 1 9 4 14 0 28 (3.7)
 Neuritis + ENL 0 0 0 0 2 5 7 (0.9)
 Neuritis + Mixed reaction 0 0 0 0 1 0 1 (0.1)
 Neuritis + Arthritis 0 0 1 0 1 0 2 (0.3)
 Neuritis + Orchitis 0 0 1 0 0 0 1 (0.1)
 Neuritis + reactional hand and foot 0 0 3 1 7 1 12 (1.6)
 Neuritis + ENL + polymorphic erythema 0 0 0 0 0 1 1 (0.1)
Reaction-free 11 42 190 10 44 38 335 (44.5)
Total 11 48 295 41 234 124 753 (100)